Mode
Text Size
Log in / Sign up

Meta-analysis finds high prevalence of adverse outcomes in African women with hyperglycaemia in pregnancyHigh Sugar in Pregnancy Risks C-Section in Africa

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note high prevalence of adverse outcomes in African women with hyperglycaemia in pregnancy.

This systematic review and meta-analysis examined the prevalence of adverse maternal and neonatal outcomes among women with hyperglycaemia in pregnancy in Africa. The study included 9,742 women across the continent, encompassing those with gestational diabetes mellitus (GDM), type 1 diabetes (T1DM), and type 2 diabetes (T2DM). The analysis synthesized data from multiple studies to provide population-level estimates, though specific study designs, settings, and inclusion criteria for individual studies were not reported in the available data. The population specifically focused on African women experiencing hyperglycaemia during pregnancy, representing an important regional perspective on this global health concern.

The intervention or exposure was hyperglycaemia in pregnancy, which included GDM, T1DM, and T2DM. No specific comparator group was reported in the available data, indicating this was a prevalence study rather than a comparative effectiveness analysis. The analysis examined outcomes across different types of hyperglycaemia without direct comparison to normoglycemic pregnancies, limiting causal interpretation. Dosing protocols, treatment approaches, and management strategies for the hyperglycaemia were not detailed in the reported findings.

Primary outcome results were not specifically reported in the available data. However, key secondary outcomes revealed substantial prevalence rates across different types of hyperglycaemia. For women with GDM, caesarean section prevalence was 46.0% (95% CI 35.7-56.4), preterm delivery prevalence was 25.2% (95% CI 12.7-40.2), and neonatal intensive care unit admission prevalence was 25.9% (95% CI 13.7-40.2). For women with T1DM, caesarean section prevalence was 57.5% (95% CI 44.9-69.7), preterm delivery prevalence was 50.7% (95% CI 16.3-84.8), and neonatal hypoglycaemia prevalence was 20.2% (95% CI 0.0-61.4). For women with T2DM, caesarean section prevalence was 60.6% (95% CI 45.5-74.8) and preterm delivery prevalence was 35.2% (95% CI 29.5-41.1). Postpartum type 2 diabetes was listed as a secondary outcome but specific prevalence data were not provided.

Additional secondary outcomes beyond those with specific prevalence data included postpartum type 2 diabetes, though numerical results for this outcome were not reported. The wide confidence intervals for many outcomes, particularly for T1DM outcomes (preterm delivery 95% CI 16.3-84.8, neonatal hypoglycaemia 95% CI 0.0-61.4), indicate substantial uncertainty in these estimates. The neonatal intensive care unit admission data for GDM (95% CI 13.7-40.2) and caesarean section data for T2DM (95% CI 45.5-74.8) also show considerable variability in the underlying studies.

Safety and tolerability findings were reported through the adverse outcomes themselves, with caesarean section, preterm delivery, neonatal hypoglycaemia, neonatal intensive care unit admission, and postpartum type 2 diabetes all identified as adverse events associated with hyperglycaemia in pregnancy. Specific rates of serious adverse events, treatment discontinuations, and tolerability assessments were not reported. The prevalence data themselves represent the frequency of these adverse outcomes in the studied population, with caesarean section rates ranging from 46.0% to 60.6% depending on diabetes type, preterm delivery from 25.2% to 50.7%, and neonatal intensive care unit admission at 25.9% for GDM.

These results should be interpreted in the context of prior research on hyperglycaemia in pregnancy, which has consistently shown increased risks of adverse outcomes globally. The prevalence rates reported in this African population appear generally higher than those reported in some studies from other regions, particularly for caesarean section and preterm delivery. However, direct comparison is limited by differences in study design, population characteristics, and healthcare systems. The findings contribute to a growing body of literature highlighting the substantial burden of hyperglycaemia-related complications in pregnancy, with this study providing important regional data from Africa.

Key methodological limitations include the fact that outcome data predominantly come from a few studies, significant heterogeneity across most outcomes, and variation in prevalence across populations. The wide confidence intervals for many outcomes reflect this heterogeneity and uncertainty. The analysis did not include a comparator group of normoglycemic pregnancies, limiting causal interpretation of the associations. Funding sources and potential conflicts of interest were not reported, and the study phase was not specified. These limitations necessitate cautious interpretation of the findings.

Clinical implications of these findings include recognition of the high burden of adverse outcomes associated with hyperglycaemia in pregnancy among African women. Healthcare providers should be aware of the elevated risks of caesarean section, preterm delivery, neonatal intensive care unit admission, and neonatal hypoglycaemia in this population. The findings support the importance of vigilant monitoring and management of hyperglycaemia during pregnancy in African settings. However, the observational nature of the data means these are associations rather than proven causal relationships, and clinical decisions should be based on individual patient assessments and available local guidelines.

Unanswered questions include how these prevalence rates compare to those in normoglycemic African pregnancies, what specific management strategies might mitigate these risks in African settings, and how healthcare system factors influence outcomes. The role of glycemic control levels, timing of diagnosis, and specific treatment approaches in modifying these risks remains unclear from this analysis. Long-term maternal and child outcomes beyond the immediate perinatal period were not addressed. More high-quality, prospective studies with appropriate comparator groups are needed to better understand the causal pathways and identify effective interventions for improving outcomes in this population.

Imagine waking up in a hospital bed after a difficult birth. You are tired, but the biggest worry is not just the pain. It is the question of whether your baby was safe. For millions of women in Africa, this fear is a daily reality. High blood sugar during pregnancy makes these risks much worse.

Diabetes is becoming more common around the world. In Africa, this trend is growing fast. When a woman has high blood sugar while pregnant, it is called hyperglycemia. This condition is not just a number on a chart. It changes the entire course of a pregnancy.

Doctors have long known that high sugar can hurt both the mother and the baby. But the scale of the problem in Africa has been unclear. Many women face long waits for care. They often lack access to the best tools to manage their sugar levels. This gap leaves families vulnerable to serious complications.

The surprising shift

For years, doctors focused heavily on gestational diabetes. This is sugar that starts during pregnancy. It is the most common form. But this study looked at all types of diabetes. It included pre-existing type 1 and type 2 diabetes.

The results were stark. Women with pre-existing diabetes faced much higher risks. They were more likely to need a C-section. They were more likely to deliver early. Their babies were more likely to need special care immediately after birth.

But here is the twist. Even women with gestational diabetes faced high risks. About half of these women developed type 2 diabetes after giving birth. This means the problem does not end when the baby is born. It often continues for the mother's life.

What scientists didn't expect

To understand why this happens, we must look at the biology. Think of insulin as a key. It unlocks the cells so sugar can enter and give us energy. In diabetes, the key is broken or missing.

During pregnancy, the body naturally produces more hormones. These hormones act like a lock that blocks the insulin key. In a healthy pregnancy, the body makes more insulin to overcome this block. But in diabetes, the body cannot make enough. Sugar builds up in the blood.

This excess sugar crosses the placenta. It goes directly to the baby. The baby's pancreas responds by making too much insulin. This causes the baby to grow too large. A large baby makes delivery very difficult. It often requires a C-section. It also puts the baby at risk for low blood sugar right after birth.

This review looked at thirty studies from across Africa. They gathered data from nine thousand seven hundred forty-two women. The countries included South Africa, Nigeria, Ethiopia, and many others.

The numbers tell a clear story. For women with gestational diabetes, nearly half needed a C-section. Over a quarter of babies needed care in the NICU. For women with pre-existing type 1 diabetes, the risks were even higher. Over half needed a C-section. Over half delivered before the due date.

For women with pre-existing type 2 diabetes, the risk of a C-section was sixty percent. The risk of early delivery was also high. These are not small numbers. They represent thousands of families facing difficult choices.

This doesn't mean this treatment is available yet.

The study highlights a major gap in care. The data comes from a limited number of studies. This means the picture is not complete. Different regions show different results. This variation suggests that local factors play a huge role.

If you are pregnant and have diabetes, talk to your doctor early. Do not wait for symptoms to appear. High blood sugar often has no warning signs. Regular checks are essential.

If you have had gestational diabetes, know that you are at risk for type 2 diabetes later. Lifestyle changes can help. Eating well and staying active are powerful tools. These steps can lower your risk of developing diabetes in the future.

The goal is to keep blood sugar in a safe range. This protects the baby from growing too large. It also protects the mother from complications. Simple daily habits make a big difference.

More research is needed to improve outcomes. Scientists need better data from more countries. We need to understand why risks vary so much. Some areas have better resources than others.

Trials for new treatments are ongoing. But approval takes time. We must build stronger health systems first. Training more nurses and doctors is a priority. Better access to insulin and monitoring tools is also needed.

Until then, awareness is our best tool. Knowing the risks helps women prepare. It encourages them to seek care early. Every step forward saves lives. The path is long, but progress is possible.

Study Details

Study typeMeta analysis
Sample sizen = 9,742
EvidenceLevel 1
PublishedJan 2026
View Original Abstract ↓
OBJECTIVE: The global prevalence of type 2 diabetes mellitus has significantly risen in recent decades, leading to a corresponding increase in the incidence of diabetes-complicated pregnancies. Hyperglycaemia in pregnancy (HIP), the most common metabolic complication encountered during pregnancy, is associated with a range of adverse maternal and foetal outcomes. This systematic review comprehensively examined the maternal, foetal, neonatal, childhood, and long-term maternal outcomes of HIP in Africa. METHODS: A systematic review of all studies investigating HIP outcomes in Africa from January 1998 to February 2025 was undertaken. We searched PubMed-MEDLINE, Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase and Web of Science databases for eligible studies. Studies were included if they were observational studies describing outcomes of HIP in Africa. For each outcome, study results were synthesised using an inverse variance heterogeneity meta-analysis with the Freeman-Tukey transformation. Heterogeneity was assessed using the I2 statistic, and publication bias was assessed using Doi plots. RESULTS: Thirty studies were included in the review, comprising 9742 participants. These studies were conducted across the following African countries: South Africa (n = 11), Ethiopia (n = 4), Nigeria (n = 3), Sudan (n = 3), Uganda (n = 2), and one each from Ghana, Algeria, Morocco, Democratic Republic of Congo, Zimbabwe, Togo, and Egypt. The most common adverse pregnancy outcomes for gestational diabetes mellitus (GDM) were caesarean section (CS) (overall prevalence 46.0%, 95% CI 35.7-56.4, I2 = 95.6%), preterm delivery (overall prevalence 25.2% (95% CI 12.7-40.2, I2 = 96.7%) and neonatal intensive care unit (NICU) admission (overall prevalence 25.9% (95% CI 13.7-40.2, I2 = 85.7%). The most common adverse pregnancy outcomes for women with preexisting type 1 diabetes (T1DM) were CS (overall prevalence 57.5%, 95% CI 44.9-69.7, I2 = 81.2%), preterm delivery (overall prevalence 50.7%, 95% CI 16.3-84.8, I2 = 92.6%), and neonatal hypoglycaemia (overall prevalence 20.2%, 95% CI 0.0-61.4, I2 = 94.6%). CS (overall prevalence 60.6%, 95% CI 45.5-74.8, I2 = 93.6%) and preterm delivery (overall prevalence 35.2%, 95% CI 29.5-41.1, I2 = 49.3%) were the most prevalent adverse pregnancy outcomes for women with preexisting type 2 diabetes (T2DM). Postpartum T2DM was the most common long-term adverse outcome of women who had GDM or hyperglycaemia first detected in pregnancy (HFDP). There was significant heterogeneity across most outcomes. CONCLUSIONS: The prevalence of adverse outcomes of HIP in Africa is high, in particular CS, preterm delivery and neonatal hypoglycaemia, with higher frequencies in pregestational T1DM and T2DM compared to GDM. Additionally, T2DM prevalence in women post-GDM is about 50%. The outcome data predominantly come from a few studies, indicating the necessity for more high-quality research to improve HIP-related maternal and child health in Africa. The high heterogeneity across most outcomes suggests that their prevalence varies across populations and underscores the need for more high-quality data. PROSPERO Registration Number: CRD42020184573.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.